What is HC Wainwright’s Estimate for VolitionRx Q1 Earnings?

VolitionRx Limited (NYSE:VNRX) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for VolitionRx in a report released on Tuesday, April 8th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for VolitionRx’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx’s Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at ($0.04) EPS and FY2026 earnings at $0.01 EPS.

Several other analysts have also commented on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research report on Monday, March 31st. StockNews.com assumed coverage on VolitionRx in a research note on Saturday, April 5th. They set a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, VolitionRx currently has a consensus rating of “Hold” and a consensus price target of $3.33.

VolitionRx Trading Up 7.4 %

Shares of VNRX opened at $0.49 on Wednesday. The firm has a 50-day moving average price of $0.57 and a 200 day moving average price of $0.63. VolitionRx has a 12-month low of $0.42 and a 12-month high of $1.02. The firm has a market capitalization of $47.69 million, a P/E ratio of -1.37 and a beta of 1.15.

Hedge Funds Weigh In On VolitionRx

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the period. Two Sigma Securities LLC acquired a new position in shares of VolitionRx in the fourth quarter valued at approximately $29,000. Northern Trust Corp increased its stake in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares during the period. Lagoda Investment Management L.P. lifted its holdings in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in VolitionRx during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

Insider Activity

In other news, CEO Cameron John Reynolds purchased 181,818 shares of the stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now directly owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This represents a 8.59 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 12.80% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.